<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02734823</url>
  </required_header>
  <id_info>
    <org_study_id>0S-15-7</org_study_id>
    <secondary_id>NCI-2016-00352</secondary_id>
    <secondary_id>0S-15-7</secondary_id>
    <secondary_id>P30CA014089</secondary_id>
    <nct_id>NCT02734823</nct_id>
  </id_info>
  <brief_title>Long Term Effects of Tyrosine Kinase Inhibitor Therapy on Ovarian Reserve and Fertility in Patients With Chronic Myeloid Leukemia or Gastrointestinal Stromal Tumor</brief_title>
  <official_title>Long Term Effects of Tyrosine Kinase Inhibitors on Ovarian Reserve and Fertility, A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot research trial studies the long term effects of tyrosine kinase inhibitor therapy
      on ovarian reserve and fertility in patients with chronic myeloid leukemia or
      gastrointestinal stromal tumor. Studying ovary imaging, ovarian reserve markers, and hormone
      levels from patients receiving tyrosine kinase inhibitor therapy may help doctors learn more
      about the effects of tyrosine kinase inhibitor therapy on ovarian function and fertility.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To collect preliminary information to help design a study to look at longitudinal changes
      in markers of ovarian reserve and menstruation in premenopausal women undergoing tyrosine
      kinase inhibitors (TKI) therapy.

      SECONDARY OBJECTIVES:

      I. Evaluate ovarian response to controlled ovarian hyperstimulation in patients who elect to
      undergo in vitro fertilization (IVF) for fertility preservation.

      OUTLINE:

      Patients undergo transvaginal ultrasound for antral follicles analysis and collection of
      serum for ovarian reserve markers and hormonal analysis before TKI therapy and at 12, 24, and
      48 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2016</start_date>
  <completion_date type="Anticipated">March 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in markers of ovarian reserve in premenopausal women undergoing tyrosine kinase inhibitor therapy for cancer</measure>
    <time_frame>Baseline to up to 1 year</time_frame>
    <description>Standard descriptive statistics and scatter plots will be used to summarize patterns by cohorts at each time point. Regression methods will be used to render data compatible with the assumption of the normal distribution. Analysis will be undertaken to obtain preliminary estimates of ovarian reserve over time and to elucidate whether TKI therapy produces a clinically meaningful change in ovarian reserve marker.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ovarian response to controlled ovarian hyperstimulation in patients who elect to undergo IVF for fertility preservation</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>The results of their stimulation protocol will be recorded.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Chronic Myelogenous Leukemia, BCR-ABL1 Positive</condition>
  <condition>Gastrointestinal Stromal Tumor</condition>
  <condition>Premenopausal</condition>
  <arm_group>
    <arm_group_label>Ancillary-Correlative (ovary imaging, hormonal analysis)</arm_group_label>
    <description>Patients undergo transvaginal ultrasound for antral follicles analysis and collection of serum for ovarian reserve markers and hormonal analysis before TKI therapy and at 12, 24, and 48 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cytology Specimen Collection Procedure</intervention_name>
    <description>Undergo collection of serum</description>
    <arm_group_label>Ancillary-Correlative (ovary imaging, hormonal analysis)</arm_group_label>
    <other_name>Cytologic Sampling</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Ancillary-Correlative (ovary imaging, hormonal analysis)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Ancillary-Correlative (ovary imaging, hormonal analysis)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ultrasonography</intervention_name>
    <description>Undergo transvaginal pelvic ultrasonography</description>
    <arm_group_label>Ancillary-Correlative (ovary imaging, hormonal analysis)</arm_group_label>
    <other_name>ULTRASOUND</other_name>
    <other_name>Ultrasound Imaging</other_name>
    <other_name>Ultrasound Test</other_name>
    <other_name>Ultrasound, Medical</other_name>
    <other_name>US</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with chronic myeloid leukemia or gastrointestinal stromal tumor undergoing TKI
        therapy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with chronic myeloid leukemia (CML), gastrointestinal stromal tumor (GIST),
             non metastatic cancer where TKI is the first line agent

          -  Premenopausal (has had menses at any time in the preceding 12 consecutive months)

          -  Has not undergone a hysterectomy or bilateral oophorectomy

          -  Willing to use non-hormonal (ie: barrier method or abstinence) as form of
             contraception during the one year of study

        Exclusion Criteria:

          -  Patients who have had chemotherapy or radiotherapy in the past

          -  Patients may not be receiving any other investigational agents

          -  Patients must not be pregnant or nursing

          -  Other medical conditions or treatments that affect hormonal levels (potentially
             confounding interpretation of results)

          -  Patients with ongoing hormonal contraception or unwilling or unable to discontinue
             will not eligible
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Irene Woo</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Irene Woo, MD</last_name>
    <phone>323-226-2850</phone>
    <email>Irene.woo@med.usc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>USC / Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irene Woo</last_name>
      <phone>323-226-2850</phone>
      <email>Irene.woo@med.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Irene Woo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2016</study_first_submitted>
  <study_first_submitted_qc>April 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2016</study_first_posted>
  <last_update_submitted>March 30, 2018</last_update_submitted>
  <last_update_submitted_qc>March 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

